Caliper Life Sciences and Xenogen Schedule Stockholder Meetings to Approve Merger
Caliper Life Sciences, Inc. and Xenogen Corporation announced that the S-4 registration statement-joint proxy statement for their previously announced pending merger was declared effective by the United States Securities and Exchange Commission on July 11, 2006, and that each company will hold a stockholder meeting on August 9, 2006. The record date for each company's stockholder meeting is the close of business on July 6, 2006.
The primary purpose of these stockholder meetings is to approve the merger agreement between Xenogen and Caliper, in the case of the Xenogen stockholder meeting, and to approve the issuance of Caliper securities to the Xenogen stockholders and warrant holders pursuant to the pending merger, in the case of the Caliper stockholder meeting. In addition, at the Caliper stockholder meeting, Caliper's stockholders will be asked to approve an increase in Caliper's authorized common stock and, because this meeting will also serve as Caliper's regular annual stockholder meeting, to elect two existing Caliper Directors to new three-year terms.
Each of Caliper's and Xenogen's Board of Directors is recommending stockholder approval of the merger under the terms set forth in the merger agreement dated February 10, 2006. Under the terms of this agreement, Caliper will issue approximately 13.2 million common shares and approximately 5.125 million warrants to purchase Caliper common shares in exchange for Xenogen's outstanding common shares and warrants.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Anton Paar acquires product line for particle characterization
LU Bioscience increases position in ProNoxis
Baco_noir
More than 97% of Pronova’s shareholders accept BASF’s offer for Pronova BioPharma
Mitoxantrone
Pleurothallis
Abbott Recognized on Dow Jones Sustainability Index (DJSI) for Fourth Consecutive Year - Abbott Only U.S.-based Fortune 100 Health Care Manufacturer to Be
Hydrolase
